Analysts have been eager to weigh in on the Healthcare sector with new ratings on Protara Therapeutics (TARA – Research Report), Cybin (CYBN – Research Report) and Roche Holding AG (RHHVF – Research Report).
Protara Therapeutics (TARA)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Protara Therapeutics, with a price target of $23.00. The company’s shares closed last Thursday at $1.45, close to its 52-week low of $1.04.
According to TipRanks.com, Fein ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Protara Therapeutics with a $24.50 average price target.
See the top stocks recommended by analysts >>
Cybin (CYBN)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Cybin today and set a price target of $5.00. The company’s shares closed last Thursday at $0.45.
According to TipRanks.com, Trucchio ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cybin with a $5.33 average price target, which is a 987.8% upside from current levels. In a report issued on November 20, Alliance Global Partners also initiated coverage with a Buy rating on the stock with a $6.00 price target.
Roche Holding AG (RHHVF)
Deutsche Bank analyst Emmanuel Papadakis maintained a Sell rating on Roche Holding AG today and set a price target of CHF225.00. The company’s shares closed last Thursday at $265.00, close to its 52-week low of $252.87.
According to TipRanks.com, Papadakis is a 4-star analyst with an average return of
Roche Holding AG has an analyst consensus of Hold, with a price target consensus of $307.31, a 14.2% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Sell rating on the stock with a CHF238.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TARA:
- Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
- Protara Therapeutics files $300M mixed securities shelf
- Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
- Protara Therapeutics reports Q3 EPS (87c), consensus (98c)
- Protara Therapeutics doses first patient in Phase 2 STARBORN-1 trial of TARA-002
